Patents by Inventor George Kukolj
George Kukolj has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11597759Abstract: Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.Type: GrantFiled: May 6, 2020Date of Patent: March 7, 2023Assignee: GILEAD SCIENCES, INC.Inventors: Tomas Cihlar, Joshua Goldsmith, George Kukolj, Craig S. Pace, Doug Rehder, Matthew R. Schenauer, Derek Dean Sloan, Heather Theresa Stephenson, Nathan D. Thomsen
-
Publication number: 20200377592Abstract: Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.Type: ApplicationFiled: May 6, 2020Publication date: December 3, 2020Inventors: Tomas Cihlar, Joshua Goldsmith, George Kukolj, Craig S. Pace, Doug Rehder, Derek Dean Sloan, Heather Theresa Stephenson, Nathan D. Thomsen
-
Publication number: 20180371086Abstract: Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.Type: ApplicationFiled: June 21, 2018Publication date: December 27, 2018Applicant: Gilead Sciences, Inc.Inventors: Tomas Cihlar, Joshua Goldsmith, Craig S. Pace, Derek Sloan, Heather Stephenson, Nathan D. Thomsen, George Kukolj, Doug Rehder
-
Publication number: 20160206678Abstract: Aspects of this invention include methods comprising administering a combination of a Compound (1) below, including particular crystalline forms thereof and pharmaceutically acceptable salts thereof, with at least one further selected HCV inhibiting compound as described herein for the treatment of Hepatitis C Viral (HCV) infection. The methods can be conducted by administering the Compound (1) and the at least one further selected HCV inhibiting compound separately or together, including as a regimen of treatment.Type: ApplicationFiled: March 31, 2016Publication date: July 21, 2016Inventor: George KUKOLJ
-
Publication number: 20150164884Abstract: Aspects of this invention include methods comprising administering a combination of a Compound (1) below, including particular crystalline forms thereof and pharmaceutically acceptable salts thereof, with at least one further selected HCV inhibiting compound as described herein for the treatment of Hepatitis C Viral (HCV) infection. The methods can be conducted by administering the Compound (1) and the at least one further selected HCV inhibiting compound separately or together, including as a regimen of treatment.Type: ApplicationFiled: February 26, 2015Publication date: June 18, 2015Inventor: George KUKOLJ
-
Patent number: 8501699Abstract: The present disclosure relates to the use and methods of manufacture of bicyclic nucleosides and nucleotides for the treatment and prevention of infectious and proliferative diseases, including microbial infections and cancer.Type: GrantFiled: September 7, 2012Date of Patent: August 6, 2013Assignee: Biota Scientific Management Pty LtdInventors: Paula Francom, Barbara Frey, Silas Bond, Alistair George Draffan, Michael Harding, Richard Hufton, Saba Hangiri, Michael John Lilly, Edward Tyndall, Jianmin Duan, Richard Bethell, George Kukolj
-
Patent number: 8415309Abstract: The present disclosure relates to the use and methods of manufacture of bicyclic nucleosides and nucleotides for the treatment and prevention of infectious and proliferative diseases, including microbial infections and cancer.Type: GrantFiled: January 11, 2012Date of Patent: April 9, 2013Assignee: Biota Scientific Managment Pty LtdInventors: Paula Francom, Barbara Frey, Jianmin Duan, Richard Bethell, George Kukolj
-
Publication number: 20130029904Abstract: Aspects of this invention include methods comprising administering a combination of a Compound (1) below, including particular en crystalline forms thereof and pharmaceutically acceptable salts thereof, with at least one further selected HCV inhibiting compound as described herein for the treatment of Hepatitis C Viral (HCV) infection The methods can be conducted administering the Compound (1) and the at least one further selected HCV inhibiting compound separately or together, including as a regimen of treatment.Type: ApplicationFiled: December 13, 2010Publication date: January 31, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventor: George Kukolj
-
Publication number: 20130018013Abstract: The present disclosure relates to the use and methods of manufacture of bicyclic nucleosides and nucleotides for the treatment and prevention of infectious and proliferative diseases, including microbial infections and cancer.Type: ApplicationFiled: September 7, 2012Publication date: January 17, 2013Applicant: BIOTA SCIENTIFIC MANAGEMENT PTY LTDInventors: Paula Francom, Barbara Frey, Silas Bond, Alistair George Draffan, Michael Harding, Richard Hufton, Saba Jahangiri, Michael John Lilly, Edward Tyndall, Jianmin Duan, Richard Bethell, George Kukolj
-
Publication number: 20120135949Abstract: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) Compound (2), or a pharmaceutically acceptable salt thereof, as herein described, and optionally (c) ribavirin, and methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient.Type: ApplicationFiled: September 23, 2011Publication date: May 31, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Wulf Otto BOECHER, Carla HAEFNER, George KUKOLJ
-
Publication number: 20120122811Abstract: The present disclosure relates to the use and methods of manufacture of bicyclic nucleosides and nucleotides for the treatment and prevention of infectious and proliferative diseases, including microbial infections and cancer.Type: ApplicationFiled: January 11, 2012Publication date: May 17, 2012Applicant: Biota Scientific Management Pty LtdInventors: Paula Francom, Barbara Frey, Silas Bond, Jianmin Duan, Richard Bethell, George Kukolj
-
Patent number: 8119607Abstract: The present disclosure relates to the use and methods of manufacture of bicyclic nucleosides and nucleotides for the treatment and prevention of infectious and proliferative diseases, including microbial infections and cancer.Type: GrantFiled: July 1, 2009Date of Patent: February 21, 2012Assignee: Biota Scientific Management Pty LtdInventors: Paula Francom, Barbara Frey, Silas Bond, Alistair George Draffan, Michael Harding, Richard Hufton, Saba Jahangiri, Michael John Lilly, Edward Tyndall, Jianmin Duan, Richard Bethell, George Kukolj
-
Patent number: 7919312Abstract: A unique HCV RNA molecule is provided having an enhanced efficiency of establishing cell culture replication. Novel adaptive mutations have been identified within the HCV non-structural region that improves the efficiency of establishing persistently replicating HCV RNA in cell culture. This self-replicating polynucleotide molecule contains, contrary to all previous reports, a 5?-NTR that can be either an A as an alternative to the G already disclosed and therefore provides an alternative to existing systems comprising a self-replicating HCV RNA molecule. The G?A mutation gives rise to HCV RNA molecules that, in conjunction with mutations in the HCV non-structural region, such as the G(2042)C/R mutations, possess greater efficiency of transduction and/or replication. These RNA molecules when transfected in a cell line are useful for evaluating potential inhibitors of HCV replication.Type: GrantFiled: March 28, 2006Date of Patent: April 5, 2011Assignee: Boehringer Ingelheim (Canada) Ltd.Inventors: George Kukolj, Arnim Pause
-
Patent number: 7893084Abstract: An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein: A is O, S, NR1, or CR1, wherein R1 is defined herein; represents either a single or a double bond; R2 is selected from: H, halogen, R21, OR21, SR21, COOR21, SO2N(R22)2, N(R22)2, CON(R22)2, NR22C(O)R22 or NR22C(O)NR22 wherein R21 and each R22 is defined herein; B is NR3 or CR3, with the proviso that one of A or B is either CR1 or CR3, wherein R3 is defined herein; K is N or CR4, wherein R4 is defined herein; L is N or CR5, wherein R5 has the same definition as R4; M is N or CR7, wherein R7 has the same definition as R4; Y1 is O or S; Z is N(R6a)R6 or OR6, wherein R6a is H or alkyl or NR61R62 wherein R61 and R62 are defined herein; and R6 is H, alkyl, cycloalkyl, alkenyl, Het, alkyl-aryl, alkyl-Het; or R6 is wherein R7 and R8 and Q are as defined herein; Y2 is O or S; R9 is H, (C1-6 alkyl), (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl, aryl, Het, (C1-6)alkyl-aryl or (C1-6)alkyl-Het, all of whichType: GrantFiled: November 26, 2008Date of Patent: February 22, 2011Assignee: Boehringer Ingelheim Canada Ltd.Inventors: Pierre Louis Beaulieu, Gulrez Fazal, Sylvie Goulet, George Kukolj, Martin Poirier, Youla S. Tsantrizos, Eric Jolicoeur, James Gillard, Marc-André Poupart, Jean Rancourt
-
Patent number: 7803944Abstract: An isomer, enantiomer, diastereoisomer, or tautomer of a compound, represented by formula I: wherein: A is O, S, NR1, or CR1, wherein R1 is defined herein; — represents either a single or a double bond; R2 is selected from: H, halogen, R21, OR21, SR21, COOR21, SO2N(R22)2, N(R22)2, CON(R22)2, NR22C(O)R22 or NR22C(O)NR22 wherein R21 and each R22 is defined herein; B is NR3 or CR3, with the proviso that one of A or B is either CR1 or CR3, wherein R3 is defined herein; K is N or CR4, wherein R4 is defined herein; L is N or CR5 wherein R5 has the same definition as R4 defined above; M is N or CR7, wherein R7 has the same definition as R4 defined above; Y1 is O or S; Z is N(R6a)R6 or OR6, wherein R6a is H or alkyl or NR61R62 wherein R61 and R62 are defined herein; a salt or a derivative thereof, as an inhibitor of HCV NS5B polymerase.Type: GrantFiled: August 15, 2006Date of Patent: September 28, 2010Assignee: Boehringer Ingelheim International GmbHInventors: Pierre Louis Beaulieu, Gulrez Fazal, George Kukolj, Eric Jolicoeur, James Gillard, Marc-Andre Poupart, Jean Rancourt
-
Publication number: 20100035836Abstract: The present disclosure relates to the use and methods of manufacture of bicyclic nucleosides and nucleotides for the treatment and prevention of infectious and proliferative diseases, including microbial infections and cancer.Type: ApplicationFiled: July 1, 2009Publication date: February 11, 2010Inventors: Paula Francom, Barbara Frey, Silas Bond, Alistair George Draffan, Michael Harding, Richard Hufton, Saba Jahangiri, Michael John Lilly, Edward Tyndall, Jianmin Duan, Richard Bethell, George Kukolj
-
Patent number: 7576079Abstract: An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein: A is O, S, NR1, or CR1, wherein R1 is defined herein; ?represents either a single or a double bond; R2 is selected from 6 or 10-membered aryl and Het, each optionally substituted with R20; provided that Het is not a 5- or 6-membered monocyclic heterocycle having 1 or 2 nitrogen heteroatoms; B is NR3 or CR3, with the proviso that one of A or B is either CR1 or CR3, wherein R3 is defined herein; K is N or CR4, wherein R4 is defined herein; L is N or CR5, wherein R5 has the same definition as R4; M is N or CR7, wherein R7 has the same definition as R4; Y1 is O or S; Z is N(R6a)R6 or OR6, wherein R6a is H or alkyl or NR61R62 wherein R61 and R62 are defined herein; and R6 is H, alkyl, cycloalkyl, alkenyl, Het, alkyl-aryl, alkyl-Het; or R6 is wherein R7 and R8 and Q are as defined herein; Y2 is O or S; R9 is H, (C1-6 alkyl), (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl, aryl, Het, (C1-6)alkyl-arylType: GrantFiled: January 17, 2006Date of Patent: August 18, 2009Assignee: Boehringer Ingelheim (Canada) Ltd.Inventors: Pierre Louis Beaulieu, Gulrez Fazal, Sylvie Goulet, George Kukolj, Martin Poirier, Youla S. Tsantrizos, James Gillard, Marc-Andre Poupart
-
Publication number: 20090087409Abstract: An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein: A is O, S, NR1, or CR1, wherein R1 is defined herein; represents either a single or a double bond; R2 is selected from: H, halogen, R21, OR21, SR21, COOR21, SO2N(R22)2, N(R22)2, CON(R22)2, NR22C(O)R22 or NR22C(O)NR22 wherein R21 and each R22 is defined herein; B is NR3 or CR3, with the proviso that one of A or B is either CR1 or CR3, wherein R3 is defined herein; K is N or CR4, wherein R4 is defined herein; L is N or CR5, wherein R5 has the same definition as R4; M is N or CR7, wherein R7 has the same definition as R4; Y1 is O or S; Z is N(R6a)R6 or OR6, wherein R6a is H or alkyl or NR61R62 wherein R61 and R62 are defined herein; and R6 is H, alkyl, cycloalkyl, alkenyl, Het, alkyl-aryl, alkyl-Het; or R6 is wherein R7 and R8 and Q are as defined herein; Y2 is O or S; R9 is H, (C1-6 alkyl), (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl, aryl, Het, (C1-6)alkyl-aryl or (C1-6)alkyl-Het, alType: ApplicationFiled: November 26, 2008Publication date: April 2, 2009Applicant: Boehringer Ingelheim (Canada) Ltd.Inventors: Pierre Louis Beaulieu, Gulrez Fazal, Sylvie Goulet, George Kukolj, Martin Poirier, Youla S. Tsantrizos, Eric Jolicoeur, James Gillard, Marc-Andre Poupart, Jean Rancourt
-
Patent number: 7439258Abstract: A compound of the formula I: wherein: X is CH or N; Y is O or S; Z is OH, NH2, NMeR3, NHR3; OR3 or 5- or 6-membered heterocycle, having 1 to 4 heteroatoms selected from O, N and S, said heterocycle being optionally substituted with from 1 to 4 substituents; A is N, COR7 or CR5, wherein R5 is H, halogen, or (C1-6) alkyl and R7 is H or (C1-6 alkyl), with the proviso that X and A are not both N; R6 is H, halogen, (C1-6 alkyl) or OR7, wherein R7 is H or (C1-6 alkyl); R1 is selected from the group consisting of 5- or 6-membered heterocycle having 1 to 4 heteroatoms selected from O, N, and S, phenyl, phenyl(C1-3)alkyl, (C2-6)alkenyl, phenyl(C2-6)alkenyl, (C3-6)cycloalkyl, (C1-6)alkyl, CF3, 9- or 10-membered heterobicycle having 1 to 4 heteroatoms selected from O, N and S, wherein said heterocycle, phenyl, phenyl(C2-6)alkenyl and phenyl(C1-3)alkyl), alkenyl, cycloalkyl, (C1-6)alkyl, and heterobicycle are all optionally substituted with from 1 to 4 substituents; R2 is selected from (C1-6)alkyl, (C3-7)cycloalkyl,Type: GrantFiled: May 21, 2004Date of Patent: October 21, 2008Assignee: Boehringer Ingelheim (Canada) LtdInventors: Pierre Louis Beaulieu, Gulrez Fazal, James Gillard, George Kukolj, Volkhard Austel
-
Patent number: 7386398Abstract: The HCV NS5B polymerase, when complexed with certain inhibitors, adopts a conformation in which the finger loop region defined by amino acid residues 18 to 35 is displaced to expose a binding pocket defined generally by amino acid residues 392, 393, 395, 396, 399, 424, 425, 428, 429, 492, 493, 494, 495, 496, 500 and 503. This newly exposed binding pocket defines a novel target in the search of further chemical entities which are capable of binding to HCV NS5B and modulating, or preferably inhibiting, the polymerase activity of HCV NS5B.Type: GrantFiled: May 7, 2004Date of Patent: June 10, 2008Assignee: Boehringer Ingelheim International GmbHInventors: René Coulombe, Pierre Beaulieu, Eric Jolicoeur, George Kukolj, Steven Laplante, Marc-André Poupart